Kymera Investor Presentation Deck

HS Case Study: Patient HS-3 Complete Clearing of Lesions and Symptoms in Patient with Moderate Disease at Baseline Day 1 - BL Day 42 45 year old Black Female with Moderate HS (HS- PGA); Baseline AN count = 7 Prior treatments: clindamycin (topical) and doxycycline Efficacy Endpoints HS-PGA Score AN Count (% Reduction) Skin Pain NRS - Worst, past week (% Change) Peak Pruritis NRS - past week (% Change) BL Moderate 7 7 6 Day 28 Day 35 Clear Clear 0 (-100) 0 (-100) 0 (-100) 0 (-100) 0 (-100) KYMERA ©2023 KYMERA THERAPEUTICS, INC. 0 (-100) Day 42 Clear 0 (-100) 0 (-100) 0 (-100) Percent change from baseline Area of swelling Beneath skin -25- -50- -75- -100- Resolution of Swelling Skin Inflammation Biomarkers* (RNAseq) '||| IIII CXCL8 IL1B PTGS2 IL36A IL17A IL5 CXCL1 GZMB IFNG *Changes at D28 PAGE 28

View entire presentation